Investment
Features
FeesSafety
Academy
More
Pluang+

Bitget expands beyond crypto with UEX strategy, adding stocks, AI trading, and institutional growth.

Protocol Fundamentals
14 Sep 2026
Tokenpost
View Source
Bullish
Bitget expands beyond crypto with UEX strategy, adding stocks, AI trading, and institutional growth.

Bitget is accelerating its growth beyond cryptocurrency by implementing its Universal Exchange (UEX) strategy, which includes new products like stock perpetual contracts, U.S. stock options, and Hong Kong stock Quanto contracts. Non-crypto assets now make up 40% of its trading volume, and its tokenized asset product rToken quickly gained over $100 million in assets. The platform also launched AI Playbook, an AI-driven trading tool, reflecting Bitget's focus on integrating AI and traditional finance with crypto. Institutional trading is growing, with a 45% increase in assets and more active market makers, as Bitget plans to enhance security, compliance, and infrastructure to support its expanding multi-asset platform.

Bitget's expansion beyond crypto is notable context for readers. For those following major cryptocurrencies on Pluang, 33 of 50 rose and 15 fell as of Sep 14, 2026 18:51 WIB. Kusama (KSM) gained 4.98% to Rp70.781 with a typical hold time of 79 days. Ripple (XRP) rose 4.50% to Rp24.729, with 63% buy orders and a 71-day hold time. Tezos (XTZ) increased 3.94% to Rp4.877, though all orders were sell with a 100-day hold time.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
2 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
2 hours ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
3 hours ago
XRP market value drops $61B in a year as Evernorth launches XRP treasury company on Nasdaq

XRP market value drops $61B in a year as Evernorth launches XRP treasury company on Nasdaq

XRP's circulating market value fell by $61.14 billion, or 42.64%, from $143.38 billion on Oct. 19, 2025, to $82.24 billion a year later, driven by a price drop from $2.39 to $1.30 despite a slight increase in circulating supply. Meanwhile, Evernorth ...

Market News
Neutral
4 hours ago
Remitly's revenue grows 20% with strong product expansion, yet valuation undervalues its potential.

Remitly's revenue grows 20% with strong product expansion, yet valuation undervalues its potential.

Remitly reported a 20% year-over-year revenue increase to $495 million, supported by 10.2 million active customers and a 197% rise in Free Cash Flow. The company is expanding its product offerings with the Remitly Card and Pay Later services, which, ...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App